Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models.
Malinee ThaneeSureerat PadthaisongManida SuksawatHasaya DokduangJutarop PhetcharaburaninPoramate KlanritAttapol TitapunNisana NamwatArporn WangwiwatsinPrakasit Sa-NgiamwiboolNarong KhuntikeoHideyuki SayaWatcharin LoilomePublished in: Cancer & metabolism (2021)
SSZ could improve CCA therapy by sensitization to CIS through killing CD44v9-positive cells and modifying the metabolic pathways, in particular tryptophan degradation (i.e., kynurenine pathway, serotonin pathway) and nucleic acid metabolism.